Media Trust Score100%

Kronos Begins Trial of Second SYK Inhibitor in FLT3-Mutated AML

In prior studies of the drug in patients with autoimmune diseases by Gilead, lanraplenib had an acceptable safety profile. San Mateo, California-based …

  • You already voted!
  • Read More